Rapid communication Open Access
Like 0


The SARS-CoV-2 Omicron variant has challenged demands to minimise workplace transmission in healthcare settings while maintaining adequate staffing. Policymakers have shortened COVID-19 isolation periods, although little real-world data have evaluated the utility. Our findings from surveillance of 240 healthcare workers from Sheffield Teaching Hospitals, England, show that 55% of affected staff could return before day 10 of isolation with over 25% eligible on day 6, pending two successive negative antigen tests. This outcome is favourable for continuity of healthcare services.


Article metrics loading...

Loading full text...

Full text loading...



  1. United Kingdom Health and Security Agency (UKHSA). COVID-19 self-isolation changes: scientific summary. London: UKHSA. [Accessed: 5 Feb 2022]. Available from: https://ukhsalibrary.koha-ptfs.co.uk/wp-content/uploads/sites/40/2022/01/20220110_Self-isolation_Scientific-Summary_Final-clean.pdf
  2. United States Centers for Disease Control and Prevention (US CDC). Interim guidance for managing healthcare personnel with SARS-COV-2 infection or exposure to SARS-COV-2. Atlanta: US CDC. [Accessed: 29 Jan 2022]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-risk-assesment-hcp.html
  3. United Kingdom Health and Security Agency. COVID-19: management of staff and exposed patients or residents in health and social care settings. London: gov.uk. [Accessed: 18 Jan 2022]. Available from: https://www.gov.uk/government/publications/covid-19-management-of-exposed-healthcare-workers-and-patients-in-hospital-settings
  4. Keeley AJ, Evans C, Colton H, Ankcorn M, Cope A, State A, et al. Roll-out of SARS-CoV-2 testing for healthcare workers at a large NHS Foundation Trust in the United Kingdom, March 2020. Euro Surveill. 2020;25(14):2000433.  https://doi.org/10.2807/1560-7917.ES.2020.25.14.2000433  PMID: 32290904 
  5. Jang S, Rhee JY, Wi YM, Jung BK. Viral kinetics of SARS-CoV-2 over the preclinical, clinical, and postclinical period. Int J Infect Dis. 2021;102:561-5.  https://doi.org/10.1016/j.ijid.2020.10.099 
  6. Nishiura H, Ito K, Anzai A, Kobayashi T, Piantham C, Rodríguez-Morales AJ. Relative reproduction number of SARS-CoV-2 Omicron (B. 1.1. 529) compared with Delta variant in South Africa. J Clin Med. 2021;11(1):30.  https://doi.org/10.3390/jcm11010030  PMID: 35011781 
  7. Brandal LT, MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. Euro Surveill. 2021;26(50):2101147.  https://doi.org/10.2807/1560-7917.ES.2021.26.50.2101147  PMID: 34915975 
  8. Pulliam JR, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. medRxiv. 2021.11.11.21266068. Preprint.
  9. National Institute of Infectious Diseases. Japan. Active epidemiological investigation on SARS-CoV-2 infection caused by Omicron variant (Pango lineage B.1.1.529) in Japan: preliminary report on infectious period. Tokyo: National Institute of Infectious Diseases; 5 Jan 2022. Available from: www.niid.go.jp/niid/en/2019-ncov-e/10884-covid19-66-en.html
  10. Garret N, Tapley A, Andriesen J, Seocharan I, Fisher LH, Bunts L, et al. High rate of asymptomatic carriage associated with variant strain Omicron. MedRxiv. 2021.12.20.21268130. Preprint.
  11. Gardner BJ, Kilpatrick AM. Estimates of reduced vaccine effectiveness against hospitalization, infection, transmission and symptomatic disease of a new SARS-CoV-2 variant, Omicron (B. 1.1. 529), using neutralizing antibody titers. MedRxiv. 2021.12.10.21267594. Preprint.  https://doi.org/10.1101/2021.12.10.21267594 
  12. Wellcome Sanger Institute. COVID-19 Genomic Surveillance. Lineages (raw). Cambridge: Wellcome Sanger Institute. [Accessed: 9 Mar 2022]. Available from: https://covid19.sanger.ac.uk/lineages/raw?area

Data & Media loading...

Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error